Alzheimer's Disease
|
0.390 |
Biomarker
|
disease |
BEFREE |
In this review, we summarize the key evidence for and against the involvement of stress-associated modulation of the CRF system in the pathogenesis of Alzheimer's disease and discuss how recent findings could lead to new potential treatment possibilities in Alzheimer's disease by using CRF-BP as a therapeutic target.
|
31641098 |
2019 |
Alzheimer's Disease
|
0.390 |
Biomarker
|
disease |
BEFREE |
Microglia express receptor for CRH that mediate neurodegeneration in AD.
|
30837843 |
2019 |
Alzheimer's Disease
|
0.390 |
Biomarker
|
disease |
BEFREE |
Sex differences are evident in the neurochemical, morphological and molecular regulation of LC neurons by CRF, providing a compelling basis for the higher prevalence of stress-related disorders such as AD in females.
|
31250157 |
2019 |
Alzheimer's Disease
|
0.390 |
Biomarker
|
disease |
BEFREE |
In recent years, a substantial amount of research has been done investigating a key stress-response mediator, corticotropin-releasing hormone (CRH), and its interactions with AD relevant processes.
|
28633663 |
2017 |
Alzheimer's Disease
|
0.390 |
Biomarker
|
disease |
BEFREE |
Our results also provide evidence for the involvement of the CRF system in noise-induced AD-like neurodegeneration.
|
29228900 |
2017 |
Alzheimer's Disease
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Phosphoproteomic results were validated by demonstrating that CRF overexpression in females was associated with increased tau phosphorylation and, in a mouse model of AD pathology, phosphorylation of β-secretase, the enzyme involved in the formation of amyloid β.
|
27752081 |
2017 |
Alzheimer's Disease
|
0.390 |
Biomarker
|
disease |
BEFREE |
Stress and corticotropin-releasing factor (CRF) have been implicated as mechanistically involved in Alzheimer's disease (AD), but agents that impact CRF signaling have not been carefully tested for therapeutic efficacy or long-term safety in animal models.
|
26555315 |
2016 |
Alzheimer's Disease
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
In particular, the major stress receptor, CRF receptor type 1 (CRFR1), modulates cellular activity in many AD-relevant brain areas, and has been demonstrated to impact both tau phosphorylation and amyloid-β (Aβ) pathways.
|
25697705 |
2015 |
Alzheimer's Disease
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, in a knockin mouse model of AD that expresses familial AD (FAD) mutations of both APP with humanized amyloid beta (hAβ), and presenilin 1 (PS1), in their endogenous patterns (APP/hAβ/PS1 animals), corticotropin releasing factor (CRF) levels are increased in key stress-related nuclei, resting corticosteroid levels are elevated, and animals display increased anxiety-related behavior.
|
22336193 |
2012 |
Alzheimer's Disease
|
0.390 |
Therapeutic
|
disease |
CTD_human |
Here we show that ligands that dissociate CRF from CRF-BP increase brain levels of 'free CRF' in AD to control levels and show cognition-enhancing properties in models of learning and memory in animals without the characteristic stress effects of CRF receptor agonists.
|
7477348 |
1995 |